Procter & Gamble Health Limited (PGHL.BO)
INR 5270.05
(0.01%)
INR 5270.05
(0.01%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 2 Billion INR | -12.42% |
| 2022 | 2.29 Billion INR | 19.19% |
| 2021 | 1.92 Billion INR | 8.89% |
| 2020 | 1.76 Billion INR | 4.38% |
| 2019 | 1.69 Billion INR | -79.8% |
| 2018 | 8.38 Billion INR | 793.11% |
| 2017 | 939.1 Million INR | 18.68% |
| 2016 | 791.3 Million INR | 47.74% |
| 2015 | 535.6 Million INR | 23.92% |
| 2014 | 432.2 Million INR | -22.66% |
| 2013 | 558.8 Million INR | -28.72% |
| 2012 | 784 Million INR | 23.12% |
| 2011 | 636.8 Million INR | 0.79% |
| 2010 | 631.8 Million INR | -3.51% |
| 2009 | 654.8 Million INR | 3.92% |
| 2008 | 630.1 Million INR | -8.44% |
| 2007 | 688.2 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 823.3 Million INR | 390.64% |
| 2023 FY | 2 Billion INR | -12.42% |
| 2023 Q4 | 167.8 Million INR | -63.96% |
| 2023 Q3 | 465.6 Million INR | -35.4% |
| 2023 Q2 | 720.7 Million INR | 9.91% |
| 2023 Q1 | 655.7 Million INR | 119.89% |
| 2022 Q4 | 298.2 Million INR | -49.62% |
| 2022 FY | 2.29 Billion INR | 19.19% |
| 2022 Q3 | 591.9 Million INR | -22.93% |
| 2022 Q2 | 768 Million INR | 20.64% |
| 2022 Q1 | 636.6 Million INR | 54.7% |
| 2021 Q1 | 553.7 Million INR | 63.38% |
| 2021 Q3 | 511.6 Million INR | 14.09% |
| 2021 Q4 | 411.5 Million INR | -19.57% |
| 2021 Q2 | 448.4 Million INR | -19.02% |
| 2021 FY | 1.92 Billion INR | 8.89% |
| 2020 Q3 | 157.7 Million INR | -76.77% |
| 2020 Q2 | 678.8 Million INR | 14.55% |
| 2020 FY | 1.76 Billion INR | 4.38% |
| 2020 Q1 | 592.6 Million INR | 21.29% |
| 2020 Q4 | 338.9 Million INR | 114.9% |
| 2019 FY | 1.69 Billion INR | -79.8% |
| 2019 Q3 | 464.62 Million INR | 0.0% |
| 2019 Q1 | 357.6 Million INR | -18.88% |
| 2019 Q4 | 488.6 Million INR | 5.16% |
| 2018 Q2 | 7.15 Billion INR | 1266.95% |
| 2018 FY | 8.38 Billion INR | 793.11% |
| 2018 Q4 | 440.81 Million INR | 8.29% |
| 2018 Q3 | 407.07 Million INR | -94.31% |
| 2018 Q1 | 523.31 Million INR | 8.33% |
| 2017 FY | 939.1 Million INR | 18.68% |
| 2017 Q4 | 483.07 Million INR | 112.68% |
| 2017 Q3 | 227.14 Million INR | -16.71% |
| 2017 Q2 | 272.71 Million INR | -13.93% |
| 2017 Q1 | 316.86 Million INR | 57.44% |
| 2016 Q1 | 285.01 Million INR | 25.12% |
| 2016 FY | 791.3 Million INR | 47.74% |
| 2016 Q4 | 201.26 Million INR | 35.74% |
| 2016 Q3 | 148.27 Million INR | -23.74% |
| 2016 Q2 | 194.43 Million INR | -31.78% |
| 2015 Q4 | 227.8 Million INR | 171.15% |
| 2015 Q1 | 125.15 Million INR | -25.77% |
| 2015 Q2 | 145.68 Million INR | 16.4% |
| 2015 Q3 | 84.01 Million INR | -42.33% |
| 2015 FY | 535.6 Million INR | 23.92% |
| 2014 Q1 | 175.83 Million INR | -16.26% |
| 2014 Q4 | 168.59 Million INR | 75.27% |
| 2014 Q3 | 96.19 Million INR | 789.61% |
| 2014 FY | 432.2 Million INR | -22.66% |
| 2014 Q2 | 10.81 Million INR | -93.85% |
| 2013 Q2 | 94.45 Million INR | -40.12% |
| 2013 Q3 | 35.56 Million INR | -62.34% |
| 2013 Q4 | 209.98 Million INR | 490.37% |
| 2013 FY | 558.8 Million INR | -28.72% |
| 2013 Q1 | 157.74 Million INR | -5.44% |
| 2012 Q1 | 258.01 Million INR | 28.02% |
| 2012 Q4 | 166.83 Million INR | 19.37% |
| 2012 Q3 | 139.76 Million INR | -30.3% |
| 2012 FY | 784 Million INR | 23.12% |
| 2012 Q2 | 200.51 Million INR | -22.29% |
| 2011 Q3 | 123.93 Million INR | -2.14% |
| 2011 Q1 | 199.94 Million INR | 0.0% |
| 2011 FY | 636.8 Million INR | 0.79% |
| 2011 Q4 | 201.53 Million INR | 62.62% |
| 2011 Q2 | 126.64 Million INR | -36.66% |
| 2010 FY | 631.8 Million INR | -3.51% |
| 2009 FY | 654.8 Million INR | 3.92% |
| 2008 FY | 630.1 Million INR | -8.44% |
| 2007 FY | 688.2 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bal Pharma Limited | 73.92 Million INR | -2618.812% |
| Achyut Healthcare Limited | 5.73 Million INR | -34962.805% |
| Alkem Laboratories Limited | 17.95 Billion INR | 88.808% |
| Divi's Laboratories Limited | 16 Billion INR | 87.439% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 113.384% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 57.319% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 1118.734% |
| Mankind Pharma Limited | 19.12 Billion INR | 89.493% |
| Medicamen Biotech Limited | 109.31 Million INR | -1738.624% |
| Medico Remedies Limited | 82.9 Million INR | -2324.104% |
| Megasoft Limited | -127.46 Million INR | 1676.734% |
| Piramal Pharma Limited | 178.2 Million INR | -1027.834% |
| Sequent Scientific Limited | -358.69 Million INR | 660.317% |
| Sigachi Industries Limited | 571.8 Million INR | -251.485% |
| Ajanta Pharma Limited | 8.16 Billion INR | 75.375% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 97.901% |
| Brooks Laboratories Limited | -195.91 Million INR | 1125.832% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 7.341% |
| Themis Medicare Limited | 435.23 Million INR | -361.77% |
| Unichem Laboratories Limited | -704.74 Million INR | 385.182% |
| Hester Biosciences Limited | 188.89 Million INR | -964.006% |
| Venus Remedies Limited | 284.9 Million INR | -605.421% |
| Indoco Remedies Limited | 984.6 Million INR | -104.123% |
| Ind-Swift Limited | 142.31 Million INR | -1312.239% |
| Aarti Drugs Limited | 1.71 Billion INR | -17.245% |
| Alpa Laboratories Limited | 167.76 Million INR | -1097.985% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | -24.438% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 96.391% |
| Granules India Limited | 4.05 Billion INR | 50.413% |
| Gufic Biosciences Limited | 861.35 Million INR | -133.33% |
| Hikal Limited | 696.02 Million INR | -188.756% |
| RPG Life Sciences Limited | 876.6 Million INR | -129.272% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 33.069% |
| Windlas Biotech Limited | 581.87 Million INR | -245.404% |
| ZIM Laboratories Limited | 172.46 Million INR | -1065.345% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 52.257% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | -49.505% |
| Jubilant Pharmova Limited | 771 Million INR | -160.674% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 93.666% |
| Bajaj HealthCare Limited | -837.93 Million INR | 339.853% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -28238.973% |
| Ipca Laboratories Limited | 5.47 Billion INR | 63.281% |
| Lasa Supergenerics Limited | -217.3 Million INR | 1024.871% |
| Laurus Labs Limited | 1.6 Billion INR | -25.182% |
| NATCO Pharma Limited | 13.88 Billion INR | 85.523% |
| Nectar Lifesciences Limited | 49.95 Million INR | -3923.624% |
| Shilpa Medicare Limited | 318.74 Million INR | -530.541% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 135.422% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 87.866% |
| Wanbury Limited | 559.56 Million INR | -259.173% |
| Wockhardt Limited | -4.63 Billion INR | 143.408% |
| Strides Pharma Science Limited | -706.14 Million INR | 384.618% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -166.361% |
| Suven Life Sciences Limited | -1.05 Billion INR | 291.271% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -346.894% |
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 67.364% |
| Eris Lifesciences Limited | 3.91 Billion INR | 48.727% |
| Lupin Limited | 19.14 Billion INR | 89.502% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 151.904% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -693.942% |
| Valiant Laboratories Limited | 3.19 Million INR | -62784.856% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 94.793% |
| FDC Limited | 3.05 Billion INR | 34.153% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 63.632% |
| Novartis India Limited | 851.9 Million INR | -135.92% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -794.716% |
| Neuland Laboratories Limited | 3 Billion INR | 33.024% |
| Morepen Laboratories Limited | 961.59 Million INR | -109.006% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -1276.443% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 2315.461% |